Furthermore, some of these studies have demonstrated Grade 3-4 neutropenia and thrombocytopenia (19% and 8%, respectively) following administration of pidilizumab (an anti-PD-1 antibody) after ASCT in patients with DLBCL, primary mediastinal B-cell lymphoma (PMBCL), and transformed indolent NHL, which are attributable to autoimmune etiology, but further studies are required to confirm this finding (20). Here, PDCD1 is linked to Thrombocytopenia.